Abstract

Breast cancer is the most common causing death in women. Tamoxifen, 1-[4-(2-dimethyl-aminoethoxy) phenyl]-1,2-diphenyl-1-butene), is a nonsteroidal antiestrogen breast cancer prevention drug causing liver toxicity. This study was carried out to elucidate the efficacy of Moringa oleifera aqueous extract against carcinogenic effect of Tamoxifen in male rats. 50 male albino rats were divided equally into five groups: control group (I); Moringa oleifera aqueous group (II) of dose (300mg/Kg/day for 6 weeks); group (III) received Tamoxifen (3mg/Kg/3 days for 6 weeks); rats received orally Tamoxifen and Moringa oleifera aqueous extract together for 6 weeks group (IV) and rats pretreated with Moringa oleifera aqueous extract then Tamoxifen with the same dose and period group (V). In group (III) there were elevate in serum activities of ALT, AST, LDH, and serum levels of TNF-α, IL-1β, Il-10, cholesterol, TG, LDL, HDL, Urea, Creatinine also liver MDA; NO; ATPase. There were decrease in serum Total protein, Albumin and liver antioxidants markers (TAC and GSH) compared to control. In conclusion, oral administration of Moringa oleifera aqueous extract improved the biochemical markers and provided antioxidant activity against the toxicity of Tamoxifen in liver tissues.

Highlights

  • Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women (Siegel et al, 2012 and Tomao et al, 2015)

  • The obtained data showed that daily oral administration of rats with moringa aqueous extract had no effect on the activities of serum ALT; AST and Lactate dehydrogenase (LDH) (2.34; -4.22 and -4.3%) respectively; while oral administration with Tamoxifen led to a significant increase (46.0; 77.17 and 42%, respectively) in their activities compared to control group

  • Our results showed that rats that received daily moringa extract resulted in non-significant changes (3.03 and 2.94% respectively) in serum total proteins and albumin while oral intoxication with Tamoxifen led to a significant decrease in their levels when compared with the control group (-10.60 and -14.70% respectively); while there improvement in their levels in group IV and group V (7.2; 3.6; 6.6 and 3.3 g/dl respectively) when compared with group III (Table 2)

Read more

Summary

Introduction

Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women (Siegel et al, 2012 and Tomao et al, 2015). 85% of all breast cancers are hormonal. They can be treated with hormone therapies, including tamoxifen and aromatase inhibitors (AIs) as anastrozole (Arimidex), letrozole (Femara) and exemestane (Aromasin)(Anderson et al, 2002). Tamoxifen has antiestrogen used in the prevention and treatment of breast cancer for both men and women through block the binding of estrogen, such as 17b-estradiol, to its receptor (McDonnell, 1999; Johnston, 2005 and Deroo et al, 2006). Tamoxifen has been shown to increase oxidative stress and induce apoptosis (Yang et al, 2013)

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.